Dopaminergic response in Parkinsonian phenotype of Machado-Joseph disease

被引：51

作者：

Buhmann, C ^{[1
]}

Bussopulos, A ^{[1
]}

Oechsner, M ^{[1
]}

机构：

[1] Univ Hosp Eppendorf, Dept Neurol, Hamburg, Germany

来源：

MOVEMENT DISORDERS | 2003年 / 18卷 / 02期

关键词：

Machado-Joseph disease; SCA; 3; D2; receptor;

D O I：

10.1002/mds.10322

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

We report on a patient with genetically proven Machado-Joseph Disease (MJD) presenting with signs indistinguishable from Parkinson's disease (PD), including levodopa response and typical levodopa-induced motor fluctuations. Only after 10 years of prolonged benefit from levodopa and different dopamine agonists (DA), the patient developed cerebellar ataxia and pyramidal signs. Preferential D3-receptor-stimulating dopamine agonists especially showed a benefit at the time, when D2 receptor binding was reduced in IBZM SPECT. This is the first report of a meaningful response to DA in MID. (C) 2002 Movement Disorder Society.

引用

收藏

页码：219 / 221

页数：3

相关论文

共 17 条

[1] DOPAMINE-RECEPTORS IN HUMAN-BRAIN - AUTORADIOGRAPHIC DISTRIBUTION OF D1 AND D2 SITES IN PARKINSON SYNDROME OF DIFFERENT ETIOLOGY [J].

CORTES, R ;

CAMPS, M ;

GUEYE, B ;

PROBST, A ;

PALACIOS, JM .

BRAIN RESEARCH, 1989, 483 (01) :30-38

[2] MACHADO-JOSEPH-AZOREAN DISEASE - A 10-YEAR STUDY [J].

FOWLER, HL .

ARCHIVES OF NEUROLOGY, 1984, 41 (09) :921-925

[3] Distribution of dopamine D3 receptor expressing neurons in the human forebrain:: Comparison with D2 receptor expressing neurons [J].

Gurevich, EV ;

Joyce, JN .

NEUROPSYCHOPHARMACOLOGY, 1999, 20 (01) :60-80

[4] The use of pramipexole in Parkinson's disease:: are its actions D3 mediated? [J].

Guttman, M ;

Jaskolka, J .

PARKINSONISM & RELATED DISORDERS, 2001, 7 (03) :231-234

[5] Spinocerebellar ataxia type 3 phenotypically resembling Parkinson disease in a black family [J].

Gwinn-Hardy, K ;

Singleton, A ;

O'Suilleabhain, P ;

Boss, M ;

Nicholl, D ;

Adam, A ;

Hussey, J ;

Critchley, P ;

Hardy, J ;

Farrer, M .

ARCHIVES OF NEUROLOGY, 2001, 58 (02) :296-299

[6] Ropinirole and pramipexole, the new agonists [J].

Hobson, DE ;

Pourcher, E ;

Martin, WRW .

CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES, 1999, 26 :S27-S33

[7]

Maj J, 2000, J NEURAL TRANSM, V107, P1369

[8] Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors [J].

Perachon, S ;

Schwartz, JC ;

Sokoloff, P .

EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 366 (2-3) :293-300

[9]

Piercey MF, 1998, CLIN NEUROPHARMACOL, V21, P141

[10] AZOREAN DISEASE OF NERVOUS-SYSTEM [J].

ROMANUL, FCA ;

FOWLER, HL ;

RADVANY, J ;

FELDMAN, RG ;

FEINGOLD, M .

NEW ENGLAND JOURNAL OF MEDICINE, 1977, 296 (26) :1505-1508